Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TYRA-300, TYRA-300 60mg
TYRA-300 /kg · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TYRA-300 0.125 mg/kg | EXPERIMENTAL | TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months. |
| TYRA-300 0.25 mg/kg | EXPERIMENTAL | TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months. |
| TYRA-300 0.375 mg/kg | EXPERIMENTAL | TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months. |
| TYRA-300 0.50 mg/kg | EXPERIMENTAL | TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months. |
| Name | Type | Description |
|---|---|---|
| TYRA-300 0.125 mg/kg | DRUG | Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol. |
| TYRA-300 0.25 mg/kg | DRUG | Subsequent dose level escalations will occur based on criteria outlined in the protocol. |
| TYRA-300 0.375 mg/kg | DRUG | Subsequent dose level escalations will occur based on criteria outlined in the protocol. |
| TYRA-300 0.50 mg/kg | DRUG | Subsequent dose level escalations will occur based on criteria outlined in the protocol. |
Inclusion Criteria: * Aged 3 to 10 years old (inclusive) at the time of consent. * Informed consent provided by parent(s) or legal guardian(s). As study participants are less than 18 years old, participants are willing and able to provide written assent (where applicable and required). * Molecular ...
TYRA-300 is an investigational small molecule being studied for low-grade non-muscle invasive bladder cancer (NMIBC), locally advanced urothelial carcinoma, and achondroplasia. It is in Phase 1 and Phase 2 clinical trials for these conditions. The drug is not yet approved and remains in clinical development.
TYRA-300 targets FGFR3, a receptor involved in cell growth and division. By inhibiting FGFR3, the drug aims to interfere with signaling pathways that can drive tumor growth in cancers with FGFR3 gene alterations, as well as address skeletal growth issues in achondroplasia.
TYRA-300 is being developed by Tyra Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TYRA. The company is conducting clinical trials to evaluate the drug's safety and efficacy across multiple indications.
TYRA-300 is in Phase 1 and Phase 2 clinical trials. A Phase 1 study is evaluating the drug in advanced urothelial carcinoma and other solid tumors with FGFR3 gene alterations. Two Phase 2 studies are assessing it in achondroplasia and low-grade non-muscle invasive bladder cancer.
TYRA-300 is being studied in three clinical trials: NCT05544552, a Phase 1 trial in advanced urothelial carcinoma and other solid tumors with FGFR3 alterations; NCT06842355, a Phase 2 trial in children with achondroplasia; and NCT06995677, a Phase 2 trial in low-grade non-muscle invasive bladder cancer.
Yes, TYRA-300 is also known as TYRA-300 60mg, TYRA-300 0.125 mg/kg, and TYRA-300 /kg. These names refer to the same investigational drug being developed by Tyra Biosciences for FGFR3-related conditions.